Medical Xpress

Combination of new drug, CB-839, with everolimus stops advanced kidney tumors growing

Munich, Germany: The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer when it ...
ascopubs.org

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).

Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC). This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not include a ...
Business Wire

CB Pharma Acquisition Corp. Announces Approval of Proposals to Extend Time to Complete Initial Business Combination

NEW YORK--(BUSINESS WIRE)--CB Pharma Acquisition Corp. (“CB Pharma”) (NASDAQ:CNLM; CNLMU; CNLMR; CNLMW) announced today that it held its extraordinary general meeting of shareholders and that at such ...
ascopubs.org

CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.

Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. Background: Glutamine utilization is a metabolic pathway ...